FDA Plans Second PCAC Meeting: Five More Peptides

The U.S. Food and Drug Administration (FDA) announced on April 15, 2026, that it will convene a second meeting of its Pharmacy Compounding Advisory Committee (PCAC) by the end of February 2027 to evaluate five more peptides.^[1] The agenda targets Cathelicidin (LL-37), Dihexa acetate, injectable GHK-Cu, Melanotan II, and Mechano Growth Factor (PEG-MGF) - all substances circulating in research, sports, and longevity circles. Peptides are small protein building blocks that act as signaling molecules in the body. Even if you don't live in the United States, this regulatory movement matters: it shapes what gets labeled "legitimate" and what gets labeled "gray market" worldwide.

Key takeaways

• The FDA plans a second PCAC meeting on the 503A Bulks List - a list under Section 503A of U.S. drug law that governs which substances compounding pharmacies may work with - by end of February 2027.^[1]
• On the agenda: Cathelicidin (LL-37), Dihexa acetate, injectable GHK-Cu, Melanotan II, and PEG-MGF.^[1]
• All five substances were removed from the FDA's 503A Category 2 list on April 22, 2026.^[2]
• A specific date and a public comment docket for this second meeting have not yet been announced.^[1]
• For users, nothing changes in the short term - the substances remain in a regulatory gray zone between "banned" and "open".^[3]

Which peptides are on the second agenda?

On the second agenda are five peptides with very different effect profiles: Cathelicidin LL-37 is an endogenous antimicrobial peptide, Dihexa acetate targets cognitive functions (such as memory and mental performance), PEG-MGF is studied for muscle regeneration, and injectable GHK-Cu as well as Melanotan II have been under heightened regulatory scrutiny for years because of documented safety incidents.^[2] I have covered those last two in my prior write-ups on BPC-157 and GHK-Cu and on Melanotan II. The lineup suggests the FDA is intentionally bundling the candidates that are most in demand in the scene.

Three of the five - Cathelicidin LL-37, Dihexa acetate, and PEG-MGF - were previously in regulatory limbo due to withdrawn nominations or missing human data. Their renewed review marks a notable policy reversal compared to the original Category 2 decision in September 2023.^[3]

What does removal from Category 2 actually mean?

Removal from Category 2 - officially "Bulk Drug Substances that Raise Significant Safety Concerns", in plain English: drug substances that raise significant safety concerns - does not mean pharmacies may now legally compound these five peptides (compounding - the pharmacy practice of preparing customized medications for individual patients), as a Goodwin analysis makes clear.^[2] It only means the FDA no longer considers them extreme-safety-risk by default and is steering them toward a neutral evaluation at PCAC instead. Until PCAC decides and the subsequent rulemaking - the formal process in which the FDA turns a recommendation into a binding rule - is complete, they remain in a legal gray zone where every 503A pharmacy carries its own liability risk.

That sends a double-edged signal: the FDA is partially walking back its safety concerns, but it is also delaying any final clarity by at least another year. In that gap, dodgy gray-market vendors love to advertise their stock as "FDA-approved" or "FDA-evaluated" - even though no evaluation has happened yet.

How does the second meeting connect to the July session?

The second PCAC session in early 2027 is a regulatory follow-up to the July 2026 meeting, where six other peptides from the same Category 2 cleanup will be evaluated - including BPC-157, TB-500, MOTS-c, Emideltide, Semax, and Epitalon, all of which also circulate in the gray market and for which FDA scientists already recommend rejection.^[1] I covered that in detail in my post on the FDA PCAC meeting of July 2026. The choreography follows a deliberate pattern: first the more familiar substances, then the riskier or less-studied ones.

PEG-MGF and Melanotan II were previously flagged in FDA records as particularly problematic because of documented side effects - and they are exactly the compounds that dominate online resale. Cathelicidin LL-37, meanwhile, had been flagged over potential effects on male reproduction.^[3]

What does this mean for you concretely?

For you as a reader, very little changes in the short term: PCAC recommendations are non-binding, and even after a positive recommendation the pharmaceutical industry estimates the subsequent rulemaking at 12-18 months - during which all five peptides will remain in a U.S. legal gray zone.^[3] In the EU and UK they remain outside authorized medicines during that window, so anyone sourcing them carries that risk personally. Keep the guidance on vendor vetting and purity checks firmly in mind, since an FDA evaluation is not a purity guarantee for research-grade vials.

I will keep tracking this development because it reshuffles the gray market as a whole. Once substances are clearly permitted or clearly banned in the United States, the line between "legitimate" and "shady" shifts internationally too.

Note: This post is for information and education only. It is not medical advice, a purchasing recommendation, or a dosing guide. Always talk to a licensed medical professional about any health-related questions.